In conclusion, our results suggest that the combinatorial use of BRAFi and diclofenac is likely to represent a new possible therapeutic approach to treat BRAF-mutated papillary and aggressive anaplastic thyroid carcinomas. The gene discussed is BRAF; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.